Expert Interview
Discussing Immix Biopharma's ongoing NEXICART-2 study evaluating NXC-201 in AL Amyloidosis
Ticker(s): IMMX, JNJ, TAK, AMGN, BMYInstitution: Memorial Sloan Kettering Cancer Center
- Attending physician on the adult BMT service at Memorial Sloan Kettering Cancer Center with an expertise in the treatment of patients with plasma cell dyscrasias including multiple myeloma (MM) and light chain (AL) amyloidosis.
- Currently treats ~50 patients with AL amyloidosis and very familiar with the literature to date for NEOD001.
- Has served as PI on multiple trials and currently working with the Amyloid Research Consortium to develop a draft guidance for the FDA with hope of accelerating drug development in AL amyloidosis.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 22, 2026
- Call Time
- 03:15 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
